These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 29242112)

  • 1. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
    Holstein SA; Avet-Loiseau H; Hahn T; Ho CM; Lohr JG; Munshi NC; Paiva B; Pasquini MC; Tario JD; Usmani SZ; Wallace PK; Weisel K; McCarthy PL
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):641-648. PubMed ID: 29242112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Al-Kadhimi Z; Costa LJ; Hahn T; Hari P; Hillengass J; Jacob A; Munshi NC; Oliva S; Pasquini MC; Shi Q; Stadtmauer EA; Waldvogel SL; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e7-e15. PubMed ID: 31526843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Ye JC; Howard A; Bhutani M; Gormley N; Hahn T; Hillengass J; Krishnan A; Landgren CO; Munshi NC; Oliva S; Owen RG; Pasquini MC; Puig N; Weinhold N; Weisel K; McCarthy PL
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e89-e97. PubMed ID: 30408566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Howard A; Avigan D; Bhutani M; Cohen AD; Costa LJ; Dhodapkar MV; Gay F; Gormley N; Green DJ; Hillengass J; Korde N; Li Z; Mailankody S; Neri P; Parekh S; Pasquini MC; Puig N; Roodman GD; Samur MK; Shah N; Shah UA; Shi Q; Spencer A; Suman VJ; Usmani SZ; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):e247-e255. PubMed ID: 32589921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
    Holstein SA; Bahlis N; Bergsagel PL; Bhutani M; Bolli N; Brownstein C; Demolis P; Foureau D; Gay F; Ghobrial IM; Gormley N; Hillengass J; Kaiser M; Maus MV; Melenhorst JJ; Merz M; Dwyer MO; Paiva B; Pasquini MC; Shah N; Wong SW; Usmani SZ; McCarthy PL
    Transplant Cell Ther; 2021 Oct; 27(10):807-816. PubMed ID: 34107340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
    Holstein SA; Asimakopoulos F; Azab AK; Bianchi G; Bhutani M; Crews LA; Cupedo T; Giles H; Gooding S; Hillengass J; John L; Kaiser S; Lee L; Maclachlan K; Pasquini MC; Pichiorri F; Shah N; Shokeen M; Shy BR; Smith EL; Verona R; Usmani SZ; McCarthy PL
    Transplant Cell Ther; 2022 Aug; 28(8):446-454. PubMed ID: 35605882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
    Glavey SV; Ghobrial IM
    Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.
    Caers J; Garderet L; Kortüm KM; O'Dwyer ME; van de Donk NWCJ; Binder M; Dold SM; Gay F; Corre J; Beguin Y; Ludwig H; Larocca A; Driessen C; Dimopoulos MA; Boccadoro M; Gramatzki M; Zweegman S; Einsele H; Cavo M; Goldschmidt H; Sonneveld P; Delforge M; Auner HW; Terpos E; Engelhardt M
    Haematologica; 2018 Nov; 103(11):1772-1784. PubMed ID: 30171031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
    Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS; Tombler ER; Stadtmauer E; Jagannath S; Anderson KC;
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):356-69. PubMed ID: 25066040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.
    Braunstein M; Niesvizky R
    Semin Oncol; 2016 Dec; 43(6):709-711. PubMed ID: 28061993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
    Merz M; Hillengass J; Goldschmidt H
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):247-51. PubMed ID: 26068597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease monitoring in multiple myeloma.
    Davies FE; Rawstron AC; Owen RG; Morgan GJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).
    Bruno B; Auner HW; Gahrton G; Garderet L; Festuccia M; Ladetto M; Lemoli RM; Massaia M; Morris C; Palumbo A; Schönland S; Boccadoro M; Kröger N
    Leuk Lymphoma; 2016; 57(6):1256-68. PubMed ID: 26735310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
    Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
    Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
    Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
    J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interpretation of minimal residual disease monitoring for response evaluation in "the guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)"].
    Chang YJ; Chen SN
    Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):332-334. PubMed ID: 32370458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.
    Gandolfi S; Vekstein C; Laubach JP; O'Brien A; Masone K; Munshi NC; Anderson KC; Richardson PG
    Clin Adv Hematol Oncol; 2018 Aug; 16(8):564-574. PubMed ID: 30148829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.